TheEdgeResearch
Home / Stocks / LITS

Lite Strategy, Inc. (LITS)

NASDAQ Healthcare Biotechnology
$0.92 ▲ +2.21%
Market Cap
$31.3M
Sector
Healthcare
Industry
Biotechnology
Beta
0.04
52-Wk Range
0.69-5.5
CEO
Justin J. File
Country
US
Currency
USD

Lite Strategy, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.92, up 2.21% on the session, giving a market capitalisation of $31.3M. On trailing twelve-month figures it carries a trailing P/E of -0.10, a net margin of 0.0%. Its beta of 0.04 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.10
Price / Sales
0.00
Price / Book
0.11
EV / EBITDA
-1.97
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
11.53
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
4
IPO date
2003-12-18
Headquarters
San Diego, CA, US
About Lite Strategy, Inc.

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Comparable companies

Lite Strategy, Inc. is most often compared with the following Healthcare names:

ACETACRVHOWLIMUXIOBTNTRBPMVPRLMDTCRXXBIT
More research on LITS
LITS technical analysis LITS TheEdge Score Compare against peers
Open full interactive analysis & DCF →